Table 5.

The FDA-approved and clinically developed antiapoptotic inhibitors in cancer therapies

Targets	Drug	Highest Phase	Indications	Company/Identifier	Status
BCL-2	PNT-2258	II	Non-hodgkin’s lymphoma	NCT01733238	Completed
		II	Diffuse large B-cell lymphoma	NCT02226965	Completed
Dual BCL-2 and BCL-XL inhibitors	Navitoclax (ABT-263)	II	Small cell lung cancer, Small cell lung carcinoma	NCT00445198	Completed
		II	Chronic lymphocytic leukemia	NCT01557777	Completed
		II	Metastatic malignant solid neoplasm, recurrent lung small cell carcinoma	NCT03366103	Terminated
		II	Refractory acute lymphoblastic leukemia, relapsed acute lymphoblastic leukemia	NCT05192889	Recruiting
		II	Metastatic malignant solid neoplasm, refractory malignant solid neoplasm, unresectable malignant solid neoplasm	NCT02079740	Active, not recruiting
		II	Malignant solid neoplasm, melanoma	NCT01989585	Active, not recruiting
		II	Chronic lymphocytic leukemia	NCT01087151	Completed
		II	Platinum-resistant or Refractory ovarian cancer	NCT02591095	Completed
		I/II	Chronic lymphocytic leukemia	NCT00481091	Completed
		I/II	Chronic lymphoid leukemia, follicular lymphoma, lymphoid malignancies, mantle cell lymphoma, non-hodgkin’s lymphoma, peripheral T-cell lymphoma	NCT00406809	Completed
		II	Prostate cancer	NCT01828476	Terminated
	Palcitoclax (APG-1252)	II	Small cell lung cancer	NCT04210037	Terminated
	ABT-737	/	Ovarian cancer	NCT01440504	Completed
	AZD0466	II	Hematological malignancies	NCT04865419	Recruiting
Selective BCL-2 inhibitors	Venetoclax (ABT-199)	Approved	Chronic lymphocytic leukemia and acute myeloid leukemia	AbbVie Inc. and Genentech Inc	/
	S55746 (S-055746, BCL201)	I	B-cell non-hodgkin lymphoma, chronic lymphocytic leukemia, multiple myeloma	NCT02920697	Completed
		I	Follicular lymphoma, mantle cell lymphoma	NCT02603445	Completed
		I	Acute myeloid leukemia, myelodysplastic syndrome	NCT02920541	Completed
	Lisaftoclax (APG-2575)	II	Chronic lymphocytic leukemia, small lymphocytic lymphoma	NCT05147467	Recruiting
		II	Multiple myeloma, amyloidosis	NCT04942067	Recruiting
		II	Breast cancer solid tumor, adult	NCT04946864	Recruiting
		II	Multiple myeloma	NCT04674514	Recruiting
		II	Chronic lymphocytic leukemia, small lymphocytic lymphoma	NCT04494503	Recruiting
		II	Relapsed/refractory acute myeloid leukemia, myeloid malignancy	NCT04501120	Recruiting
		I/II	Acute myeloid leukemia	NCT04964518	Recruiting
BCL-XL inhibitors	ABBV-155	I	Advanced solid tumors	NCT03595059	Active, not recruiting

Source: All the information is derived from ClinicalTrials.gov (https://www.clinicaltrials.gov) and the United States Food and Drug Administration.gov (https://www.fda.gov/)